Day 2: Thursday, September 14, 2017

Session 4A: Digital Pathology Meets Biobanking

  Dan Milner
Dan Milner, MD, MSc, Chief Medical Officer, ASCP: Dr. Milner completed his MD at the University of Alabama School of Medicine in 2000 and his residency/fellowship in anatomic pathology/clinical pathology/microbiology at the Brigham and Women’s Hospital in 2005. Before joining ASCP, Dr. Milner spent 10 years as faculty at Harvard where he taught pathology, microbiology, and infectious disease, was the primary lead for infectious disease consultations in AP/CP, and was the recipient of numerous research grants in the areas of malaria and HIV. In addition to these accomplishments, Dr. Milner began working in Africa in 1997 as a medical student and has built an international reputation as an expert in cerebral malaria. In parallel with this, he has been heavily involved in pathology capacity building in many countries and, most notably, lead the team that built an anatomic pathology laboratory in Rwanda and Haiti for advance cancer diagnostics. In his current role, he serves as the Director for the Center for Global Health at ASCP, leads all PEPFAR activities with ASCP (lab strengthening, x 5+ countries), and leads the Cancer Diagnosis and Treatment in Africa Initiative (telepathology, 20+ countries). Dr. Milner is the author of over 100 publications and has presented nationally and internationally on his work in more than 15 countries.
  Tiina Vesterinen
  Tiina Vesterinen works as a coordinator both in the Helsinki Biobank and in the Institute for Molecular Medicine Finland (FIMM). Helsinki Biobank, part of the Helsinki University Hospital, is the largest hospital-integrated biobank in Finland while FIMM, part of the University of Helsinki, is an international research institute focusing on human genomics and personalised medicine.

Tiina Vesterinen has been involved in biobanking since 2009. She was the coordinator of the Helsinki Urological Biobank and is a member of the Steering Group of the Finnish Hematology Registry and Biobank (FHRB). She has established a molecular pathology laboratory at FIMM as well as been a key person in developing Helsinki Biobank’s tissue processing facility. At the moment, she is responsible for answering sample and data enquiries addressed to the Helsinki Biobank.

Tiina has been closely involved in national BBMRI.fi operations as well as in Nordic Biobank Forum. She has a Master’s degree in clinical laboratory science from the University of Oulu, Finland, and is preparing her doctoral thesis on pulmonary carcinoid tumors. In her thesis work, she is utilising digital pathology as well as the samples and data from Finnish biobanks.

  Daniel Catchpoole
  In 2001, Associate Professor Catchpoole was appointed head of the tumour bank at The Children’s Hospital at Westmead, where he has established the biospecimens research group within the Children’s Cancer Research Unit of The Kids Research Institute. Since 2001, his scientific achievements and publications have primarily focused on the assessment of childhood tumours, with specific attention given to acute lymphoblastic leukaemia and neuroblastoma.

A/Prof Catchpoole’s research focus has centred on translational research through gene expression profiling of paediatric tumours. Recent publications have dealt with the assessment of gene expression signatures proposed to identify cancer patients at risk of treatment failure. This work has lead to his current research developing a systems biology approach to the assessment of cancer patients which includes the implementation of the data-mining and visualisation of complex multidimensional biomedical data derived from various high-throughput applications.

A/Prof Catchpoole is expert in building the necessary frameworks essential for active translational research activity in cancer. This includes experience of basic research into cell and molecular biology, knowledge of clinical pathways through medical institutions including the pathology departments practices, everyday management of biobanks and linkage to required clinical data, the generation of complex genomic and biomedical dataset by high-throughput technologies (eg microarray and next generation sequencing) and the high-end computational analysis of complex multi-dimensional data to draw out actionable knowledge which has clinical relevance. Consequently, A/Prof Catchpoole brings with him extensive real-world experience in the application of governance and regulatory requirements around which translational research must be practiced. He has experience in the micro-management of a team of research professionals as well as the strategic management of valuable research infrastructure with a public hospital.

He has built a strong record for professional networking bringing groups into collaborative arrangements around singular themes and opportunities from across the nation. This includes being a founding member and first president of The Australasian Biospecimens Network Association. His leadership in these and other areas has been recognised across the translational research disciplines and has contributed to a number of committees at local, state and national levels.

Finally, A/Prof Catchpoole is an innovative and strategic thinker, creating novel but productive projects which enhance our understanding of the translational research in paediatric cancer.

  Gwen Dackus
Gwen is a MD and PhD student working for Sabine Linn at the Molecular Pathology department of the Netherlands Cancer Institute.  An aspiring pathologist herself, she coordinated a population-based project to establish a cohort of adjuvant systemic treatment naive breast cancer patients diagnosed ≤40 years of age, called PARADIGM. For PARADIGM, the study team collected observational data from the Netherlands Cancer Registry and ~16,000 archival FFPE tissue samples on 2,777 patients. A workflow including digital pathology was established to secure project feasibility. Information and materials, including FFPE blocks, (digitalized) H&E slides, TMAs, DNA and RNA were placed in the PARADIGM biobank for future studies.

Gwen would like to share the experience and insights she gained in conducting PARADIGM. During her presentation at the 2017 Global Biobanking Week she will discuss the PARADIGM project with a focus on the advantages and disadvantages of incorporating digital pathology in a biobanking workflow. For further information and questions you can find Gwen on LinkedIn.

  Marcel Koek
  Coming soon.

Session 4B: Utlisation & Valuation and Public Trust

  Derick Mitchell
  Derick Mitchell, PhD is the Chief Executive of IPPOSI – the Irish Platform for Patient Organisations, Science and Industry. IPPOSI (www.ipposi.ie) is a unique, patient-led partnership between patient groups, scientists, clinicians, industry and other key decision makers, which builds consensus on issues relevant to all involved in delivering health innovations to people with unmet medical needs. Derick has over ten years experience of working in patient engagement, scientific communications, multi-stakeholder management and advocacy at both the national and European level. From 2011-2015, Derick was Communications Manager of the EU Joint Programme – Neurodegenerative Disease Research (JPND). Derick leads IPPOSI’s participation in EUPATI - a unique initiative to develop an EU-wide Patient Training Academy. He is also a board member of the Health Informatics Society of Ireland, the eHealth Ireland committee, the Medical and Life Sciences Committee of the Royal Irish Academy as well as the oversight group on implementation of the National Rare Disease Plan for Ireland. Derick graduated with a BSc (Hons) in Biotechnology from NUI Galway (2000) followed by a PhD in Molecular Medicine from University College Dublin (2004). Outside of IPPOSI, Derick spends his free time attempting to influence his two toddler daughters.
  Gesine Richter
  Research fellow of biomedical ethics at the Institute of Epidemiology, Christian-Albrechts-University Kiel, Germany.
  Lisette Eijdems
  Lisette Eijdems is a molecular biologist by training. She currently works as scientific policy advisor on research data and biobanking at the University Medical Center Groningen (UMCG) in the Netherlands. She did her PhD research on multi-drug resistance mechanisms at the National Cancer Institute (NKI/AvL, Amsterdam) and worked as a postdoctoral researcher at the Cancer Institute of UNM (University of New Mexico, Albuquerue, USA). Back in the Netherlands she became involved in the development and implementation of the UMCG Research Policy subsequently as head of the research office (dept.), of the healthy ageing programme and currently for research data and biobanking. Biobank/cohort studies are a red line in her carrier. From NIH-funded research on the AML cohort of the South West Oncology Group (SWOG), to the founding group of the LifeLines Biobank and Cohort study, the central expert team of the national Parelsnoer Institute (PSI), and the UMCG Biobanking Board. Currently she has a leading role in local and national programmes on data and biomaterials for research, as in the national BBMRI-NL 2.0, especially on sustainable and interactive biobanking.
  Heidi Carmen Howard
  Heidi Carmen Howard is a senior researcher at the Centre for Research Ethics and Bioethics, Uppsala University. She has expertise in both genetics (PhD McGill) as well as Bioethics (MSc, KULeuven) and studies the ethical, legal and social issues (ELSI) of new technologies and approaches in genomics. Current areas of focus include direct-to-consumer genetic testing, the translation of NGS from the lab to the clinic and the responsible management of gene editing technologies. Dr. Howard is chair of Work Group 2 on consumer genomics of the European funded CHIPME COST ACTION. She is also an active and productive member of the European Society of Human Genetics ELSI group (the Public and professional policy committee) as well as of the Common Service ELSI team of BBMRI-ERIC. She is a visiting scholar at the Sanger Welcome Trust Campus (Hinxton, UK), the EURAC (Bolzano, Italy), and KULeuven (Leuven, Belgium).
  Peter Riegman
  Peter Riegman is a molecular biologist heading the Erasmus MC Tissue Bank, where fresh frozen tissue and pathology archival FFPE materials for medical research under secondary use is available according to ISO 15189:2012 standards. He was involved in the European projects: EurocanPlatform (WP leader of Biobanks), BIOPOOL, SPIDIA, BBMRI, EuroBoNeT and coordinated the TuBaFrost project 2003-2006. He was co-opted board member and chair of the OECI working group biobanking 2006-2010. In 2008 Peter became ISBER president-elect, and 2009-2010 ISBER president, followed by past president until 2011. At the end of 2010 he was elected vice president of ESBB (ISBER chapter) to become president in 2011, when he also became section editor in the editorial board of Biopreservation and Biobanking and member of the international steering committee of P3G. From 2012 he became UMC-coordinator for the pearl string initiative for Erasmus MC. That same year he joined through NEN the CEN/TC140WG3 and ISO/TC212WG4 to write sample technical standards, now implemented together with BBMRI-ERIC.

Session 4C: Academic-Industrial Collaborations and Partnerships

  Larson Hicks
  Larson Hicks is the Clinical Account Executive at Conversant Biologics, based in Huntsville, Alabama (USA), responsible for all clinical site development efforts at Conversant Bio. Prior to this role, Larson headed up Conversant's biobank consulting practice and spear-headed the 2015 Biobank Financial Sustainability Grant, a partnership with ISBER to offer a $50K grant to support business strategy planning at a biorepository struggling with financial sustainability.

Larson's background is in sales, startup consulting, product management/marketing, and concert promotion. Larson is an avid rugby fan and the proud father of five children.

  Daniel Simeon-Dubach
  Daniel Simeon-Dubach, MD, MHA is the owner of Medservice, a biobanking consulting and service company located in Walchwil, Switzerland. He earned both his MD and his Master of Health Administration (MHA) from the University of Bern, Switzerland. He has been in biobanking for more than 10 years. His research and publication focus is in biobank sustainability, biomedical reproducibility, process and quality management, as well as collaboration between academia and industry. He has co-organized and co-chaired a series of symposia on sustainability at different ISBER annual meetings. He has conducted several surveys amongst biobankers on issues of collaboration and on sustainability.

He is in the marketing committee for the GBW 2017 in Stockholm. He is chair of ISBER Standards Advisory Committee. He has served on the ISBER program committees over the past few years and is a member of the ISBER program committee for 2018. He is section editor for biobanking management of the journal Biopreservation and Biobanking and member of the editorial board of the journal Synergy.

  Balwir Matharoo-Ball
  Dr. Balwir (Bal) Matharoo-Ball has a wealth of experience in academic research as well as the NHS. Bal has worked for the Nottingham Health Science Biobank (NHSB) since January 2011 and is currently the deputy director. In this role her principal interests have been to align the resources of the NHS, as a single service provider, and provide a unique platform for translational and stratified medicine in the UK. Part of this initiative has been a novel policy of the co-evolution of biobanking and informatics resources within the NHS. Bal is chair of the NHSB Access Committee and Ethics and Public Patient Involvement (PPI) lead and a member of the PPI Strategy Board for Nottingham University NHS Trust. She is also a co-applicant on the national virtual Breast Cancer Now Tissue Bank initiative which has secured over £3 million in grant funding. Bal has been a member of European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) and also International Society for Biological and Environmental Repositories (ISBER) since 2012. For the past 3 years Bal has been a member and active contributorof the ESBB Programme Committee. Recently Bal has been given the delightful position to be chair of ESBBTranslate working very closely with Dr. Christina Schroeder and Dr. Oliver Gros from Fraunhofer Institute in Germany. Bal is also a reviewer for the Biopreservation and Biobanking journal.
  Anne Hedvig Morgenstierne Sundet
  Anne H. Morgenstierne Sundet started working as a biomedical scientist in a routine pathology lab at St. Olavs University Hospital in 2000 where she participated in collecting fresh tissue for biobanking. In 2010, she worked on a project at NTNU to modernise and facilitate a large collection of serum samples from the 1980's. Since then she has worked as an engineer at a molecular research lab at NTNU and Biobank1. The last years she has worked as an executive officer at Biobank1 (a regional clinical research biobank of central Norway) together with studying for a master’s degree where her project deals with commercialisation of clinical biobanks.
  Lill Anny Gunnes Grøseth
  Lill Anny Gunnes Grøseth has worked in the field of biobanking for more than 15 years. Over the last 10 years she has been the daily manager of the national research biobank for multiple myeloma where blood and bone marrow samples are collected. She is also a member of the board for this biobank. She started out as a biomedical laboratory scientist in 1992 working in a routine microbiology lab at Nordlandsykehuset, Bodø. From 1994-2000 she worked at the National Hospital, Oslo, as a part of a research team working with hematopoietic stem cells. After this period, she worked at a clinical hematological routine lab at St. Olavs University Hospital and at the Multiple Myeloma group, NTNU, in Trondheim. During the last 16 years biobanking gradually has become an increased part of her responsibilities. Now she works in biobanking full time as a senior biomedical laboratory scientist at Biobank1 (a regional clinical research biobank of central Norway).

Session 5: International Biobanking Summit VI - Global Biobanking Going Mobile?

  Bartha Knoppers
Bartha Maria Knoppers, PhD (Comparative Medical Law), is a Professor and Director of the Centre of Genomics and Policy, Faculty of Medicine, Human Genetics, McGill University.

She holds the Canada Research Chair in Law and Medicine and is the founder of the Population Project in Genomics (P3G) and CARTaGENE, Quebec’s population biobank. Chair of the Ethics Working Party of the International Stem Cell Forum (2005-2015); Co-Chair of the Sampling/ELSI Committee of the 1000 Genomes Project (2007-2014); Chair of the Ethics and Governance Council of the International Cancer Genome Consortium (2009-17 ); and Co-Chair of the Regulatory and Ethics Working Group of the Global Alliance for Genomics and Health.

Dr. Knoppers is the recipient of four Doctorates Honoris Causa, she is Fellow of the American Association for the Advancement of Science (AAAS), the Hastings Center (bioethics), the Canadian Academy of Health Sciences (CAHS) and, in 2016, was named Fellow of the Royal Society of Canada. She is also an Officer of the Order of Canada and of Quebec.

  Megan Doerr
  A former botanist and middle school teacher, Meg Doerr joined the genetic counseling community in 2006. Meg led the clinical development and implementation of Cleveland Clinic's family history and risk assessment tool before joining the Governance team at Sage Bionetworks in 2015. At Sage, Meg’s efforts have been concentrated on supporting innovative, participant-centric approaches in open science. Her work has a strong focus on app-based research, including the ELSI issues associated with informed consent, research participation, and data sharing for secondary use in entirely remote, mobile platform-based research studies including for the All of Us Research Program.
  Pascal Borry
  Coming soon.
  Edward Dove
Edward (Ted) Dove is Lecturer in Risk and Regulation at the School of Law, University of Edinburgh, and Deputy Director of the Mason Institute for Medicine, Life Sciences and Law. He recently submitted his PhD, which explored from a legal-anthropological perspective the role of NHS research ethics committees in a changing health research regulatory environment. From 2011 until 2014, Ted was an Academic Associate at the Centre of Genomics and Policy at McGill University in Montreal. Ted’s primary research interests are in the areas of regulation of biomedical research, research ethics oversight, health-related data access and sharing, and governance of international research collaboration. He is the Editor-in-Chief of SCRIPTed, an online, peer-reviewed open access journal dedicated to law, medicine, science and technology; he is also the Case Comments Editor for Medical Law International.
  Heidi Carmen Howard
Heidi Carmen Howard is a senior researcher at the Centre for Research Ethics and Bioethics, Uppsala University. She has expertise in both genetics (PhD McGill) as well as bioethics (MSc, KULeuven) and studies the ethical, legal and social issues (ELSI) of new technologies and approaches in genomics. Current areas of focus include direct-to-consumer genetic testing, the translation of NGS from the lab to the clinic and the responsible management of gene editing technologies. Dr. Howard is chair of Work Group 2 on consumer genomics of the European funded CHIPME COST ACTION. She is also an active and productive member of the European Society of Human Genetics ELSI group (the Public and professional policy committee) as well as of the Common Service ELSI team of BBMRI-ERIC. She is a visiting scholar at the Sanger Welcome Trust Campus (Hinxton, UK), the EURAC (Bolzano, Italy), and KULeuven (Leuven, Belgium).
  Mark Rothstein
  Coming soon.

Session 6A: Sustainability in Biobanking: Past, Present, and Future?

  Peter Watson
Peter Watson, MB, BChir, FRCPC, is Professor of Pathology and Staff Pathologist and Senior Scientist at the BC Cancer Agency, British Columbia, Canada. He is the Director of Biobanking and Biospecimen Research Services (BBRS) which is a research infrastructure group that encompasses an active biobank and biobanking support unit (Tumour Tissue Repository (BCCA-TTR) at the BC Cancer Agency and Office of Biobank Education and Research (UBC-OBER) at the Department of Pathology, University of British Columbia). Our goals are to support the establishment of small and large biobanks for biospecimen based translational research and promote access, quality, and standardization through delivery of education and training and communication of best practices. He also leads the Canadian Tissue Repository Network (CTRNet) and is deputy editor for Biopreservation and Biobanking, the journal of the International Society for Biological and Environmental Repositories (ISBER). Over the past 30 years he has maintained an active clinical pathology practice focused on breast cancer and a research laboratory program focused on elucidating mechanisms of progression, understanding the intratumoral immune response, and identifying biomarkers to guide response to therapies in breast cancer. He is author of over 180 research and biobanking publications.
  Daniel Simeon-Dubach
  Daniel Simeon-Dubach, MD, MHA is the owner of Medservice, a biobanking consulting and service company located in Walchwil, Switzerland. He earned both his MD and his Master of Health Administration (MHA) from the University of Bern, Switzerland. He has been in biobanking for more than 10 years. His research and publication focus is in biobank sustainability, biomedical reproducibility, process and quality management, as well as collaboration between academia and industry. He has co-organized and co-chaired a series of symposia on sustainability at different ISBER annual meetings. He has conducted several surveys amongst biobankers on issues of collaboration and on sustainability.

He is in the marketing committee for the GBW 2017 in Stockholm. He is chair of ISBER Standards Advisory Committee. He has served on the ISBER program committees over the past few years and is a member of the ISBER program committee for 2018. He is section editor for biobanking management of the journal Biopreservation and Biobanking and member of the editorial board of the journal Synergy.

  Georges Dagher
  Georges Dagher, senior investigator (Directeur de Recherche) at Inserm (Paris, France) accomplished most of his career in pathophysiological and clinical research at Necker Hospital (1979-1984), College de France (1985-1993) and Faculty of medicine Broussais-Hotel Dieu (1994-2004). He joined the physiological laboratory (Cambridge, UK) for a post-doc fellowship (1983-85) and was a special guest to physiological laboratory, Harvard Medical School (Boston, US, 1982, 1984). Georges Dagher published about 100 papers in international peer-reviewed journals on hypertension, arterial hypertrophy, obesity and lipid metabolism, manic depression, renal physiology, and transmembrane ion transport. He was the director of BIOBANQUES infrastructure (Inserm US 13), a French infrastructure that regroups 85 biobanks (2012-2017); the coordinator of biological resources centres at Inserm (2006); the director of clinical research infrastructures at Inserm (2006-2009) and the deputy director of the department of clinical research at the Public Health Institute, Inserm, France (2009-2011). He participated actively to the preparatory phase of the pan-European Biobanking and Biomolecular Research Infrastructure (BBMRI-ERIC). In this preparatory phase he was a leading figure of the coordination committee and the leader of a work package on funding and financing. Later, when the infrastructure was set up as an ERIC, he was the vice chair of the Assembly of Members and member of the coordination body. He is also a member of BIOSHARE and BBMRI- LPS within the 7th EU framework program. He contributed to the OECD best practice guidelines for biological resource centres and the OECD guidelines on human biobanks and genetic databases. He participated in the elaboration of the French norm for biobanks NF S96-900 norm and the convenor of an ISO committee drafting an international standard for biobanking. He is a delegate of several French institutions to European and international committees or meetings (OECD, ESF, ERA, ALLEA, EASAC…) and a number of expert committees focusing on the issues related to biobanks within Europe and internationally. He is an expert to the Austrian Federal Ministry of science and research (BMWF) and Genome Quebec. He was also a member of the Inserm ethics committee (ERMES) and the Institutional Review Board (IRB).
  Sofie Bekaert
  Coming soon
  Joerg Geiger
  Education:

  • 2016 Habilitation in Clinical Biochemistry and Pathobiochemistry, University of Wuerzburg; Doctoral dissertation: “Systems Biological Analysis of Platelet Function Regulation by Cyclic Nucleotides and ADP”
  • 1996 PhD in physical chemistry and biochemistry; PhD Thesis: "Biophysical and Biochemical Aspects of Human Platelet Calcium Regulation"
  • 1989 University diploma in physical chemistry; Diploma thesis: "Evidence for Raman Optical Activity in Coherent Anti-Stokes Scattering Spectroscopy"

Employment:

  • 6/2012 - present: Director of the fluid biomaterials division at the Interdisciplinary Bank of Biological Materials and Data Wuerzburg (ibdw) at University of Wuerzburg
  • 2003 - 5/2012: Vice-director of the Institute for Clinical Biochemistry and Pathobiochemistry at the University Hospital Würzburg
  • 2002 - 2003: Senior scientist at the Institute for Clinical Biochemistry and Pathobiochemistry at the University Hospital Würzburg
  • 2001 - 2002 :Project manager at vasopharm BIOTECH GmbH, Würzburg/Gießen
  • 1999 - 2000: Postdoctoral researcher at the Institute for Clinical Biochemistry and Pathobiochemistry at the University Clinic Würzburg
  • 1996 - 1999: Postdoctoral fellow at the Interdisciplinary Center for Clinical Research (IZKF, „Interdisziplinäres Zentrum für Klinische Forschung“), University of Würzburg
  • 1995 - 1996: Research assistant at the Research Institute for Molecular Pharmacology (FMP, „Forschungsinstitut für Molekulare Pharmakologie“), Berlin, Germany

Research Interests:

  • Human Platelet Signaling and Regulation by Nucleotides and Prostanoids
  • Systems biology of platelet signal transduction
  • Stability of cryo-samples
  Alison Parry-Jones
  Alison Parry-Jones (BSc, MA, PhD, MRSC) is the manager of the Wales Cancer Bank (WCB). She is responsible for the day to day running of the WCB and is based at the University Hospital of Wales in Cardiff. She is the designated individual on the WCB licence issued by the Human Tissue Authority and is therefore responsible for governance and compliance across all WCB sites in Wales. She has extensive project management experience in academia and is a PRINCE2 registered practitioner. Her background is in analytical chemistry and before moving into project management she worked in bioanalytical laboratories specialising in phase I and II clinical research. In 2012 she completed an MA in medical ethics and law.

She is the Director-at-Large for the Europe, Middle East and Africa region for the International Society for Biological and Environmental Repositories (ISBER), and was a co-chair of the Scientific Program Committee for the ISBER 2017 annual conference in Toronto. She is one of two UK representatives on the common service ELSI team for the European BBMRI consortium and is a member of the Steering Committee for the UKCRC Tissue Directory and Coordination Centre, as well as being an executive member of the Marble Arch international biobank leaders group.

Session 6B: Biobanks and Electronic Health Records

  Olli Carpen
  Olli Carpén, MD, PhD, is professor of pathology at the University of Helsinki, Finland, scientific director of Helsinki Biobank (www.hus.fi/en/about-hus/helsinkibiobank) and senior consultant of diagnostic pathology at Helsinki University Hospital. He earned his MD and PhD degrees at the University of Helsinki, and continued as a post-doc at the Center for Cancer Research, Harvard Medical School. For the last decade, he has been actively involved in establishing the Finnish biobank network and especially in building the first Finnish hospital-integrated biobanks, Auria Biobank and Helsinki Biobank. His major focus is in combination of patient-derived biobank samples with comprehensive longitudinal electronic health information to create novel innovation platforms. His main research interests include prognostic and predictive biomarkers in gynecological and colorectal cancer and melanoma. He is an author of around 200 scientific publications and holds several diagnostic patents/patent applications.
  Henrik Edgren
  Henrik is Chief Scientific Officer at MediSapiens, with responsibility for the scientific direction of the company, as well as management of the MediSapiens data team. He obtained his PhD in cancer bioinformatics from the Faculty of Medicine at the University of Helsinki, including ground breaking work on fusion gene detection from RNA-sequencing data. He joined MediSapiens in 2013 from the Institute for Molecular Medicine Finland, where he was working on translation of sequencing results in leukemia patient care.
  Gerrit Meijer
Gerrit Meijer is professor of pathology with a special interest in gastrointestinal oncology and translational research. He is head of the Department of Pathology and Group leader at the Netherlands Cancer Institute/Antoni van Leeuwenhoek.

Professor Meijer leads a translational research group that focuses on gastrointestinal cancer. This involves omics based tumour profiling, using DNA, RNA and proteomics based techniques, in order to stratify patient groups and arrive at individual tailored therapies. Furthermore, genomic and proteomics profiling of pre-malignant lesions is used for biomarker development to improve (colorectal) cancer screening. This program was and is supported with grants from KWF, ZonMW, MLDS en CTMM. In 2014 Gerrit Meijer was granted the KWF Stand Up To Cancer “Dream Team” grant for early detection of colorectal cancer.

In extension to his research he is involved in the development of (inter-)national research infrastructures for biobanking and research IT, as co-chair of Health-RI, PI of TraIT, national co-director of EATRIS and scientific co-director of BBMRI-NL.

  Markus Kreuzthaler
  Markus Kreuzthaler completed his studies (BSc, MSc) in telematics at the Technical University of Graz, Austria in 2007, focusing on embedded computer vision and medical informatics. After a year of working experience in industrial machine vision, he joined the Institute for Medical Informatics, Statistics and Documentation at the Medical University Graz, where he focused on applied clinical natural language processing methods for information extraction and content retrieval in hospital-based application scenarios. After finishing his PhD in 2015 under the supervision of Prof. Schulz (Medical University of Graz) he joined the Austrian biomarker research company CBmed in 2016, where he has been working on the extraction of phenotype-related information entities from clinical text to support clinical biomarker research.
  Anna Carreras Nolla
  Anna Carreras obtained her degree in biology at the University of Barcelona in 2001. After some months in the department of immunology and animal physiology in the Universitat Autònoma of Barcelona, she moved to EEUU to work as a research technician in the department of pathobiology of the School of Veterinary Medicine (University of Pennsylvania, Philadelphia).

In 2003 she returned to Spain and joined the Center for Genomic Regulation (CRG), working as laboratory technician in the department of genes and diseases, led by Dr. Xavier Estivill. Later she moved to the genotyping unit of the National Center for Genotyping (CeGen) in CRG.

After almost 10 years working in human genetics, in 2011 she started working as production manager at the National Center for Genomic Analysis (CNAG). As head of the production department, she participated in the scientific projects carried out, expanding her experience in molecular genetics and sequencing.
Currently and since 2013, she works at the Institut Germans Trias i Pujol (IGTP) as laboratory manager in the Program of Predictive and Personalized Medicine of Cancer (PMPPC). She is currently involved in the GCAT Project, Genomes for Life, a prospective study of the genomes of Catalonia, led by Dr. Rafael de Cid. She heads participant recruitment, sample processing, and laboratory work. The main line of research of the project is to study the genetic and environmental factors that lead to the appearance of chronic illnesses in the population.

Session 6C: International Biobanking Harmonisation, Standardisation, and Globalisation

   Georges Dagher
Georges Dagher, senior investigator (Directeur de Recherche) at Inserm (Paris, France) accomplished most of his career in pathophysiological and clinical research at Necker Hospital (1979-1984), College de France (1985-1993) and Faculty of medicine Broussais-Hotel Dieu (1994-2004). He joined the physiological laboratory (Cambridge, UK) for a post-doc fellowship (1983-85) and was a special guest to physiological laboratory, Harvard Medical School (Boston, US, 1982, 1984). Georges Dagher published about 100 papers in international peer-reviewed journals on hypertension, arterial hypertrophy, obesity and lipid metabolism, manic depression, renal physiology, and transmembrane ion transport. He was the director of BIOBANQUES infrastructure (Inserm US 13), a French infrastructure that regroups 85 biobanks (2012-2017); the coordinator of biological resources centres at Inserm (2006); the director of clinical research infrastructures at Inserm (2006-2009) and the deputy director of the department of clinical research at the Public Health Institute, Inserm, France (2009-2011). He participated actively to the preparatory phase of the pan-European Biobanking and Biomolecular Research Infrastructure (BBMRI-ERIC). In this preparatory phase he was a leading figure of the coordination committee and the leader of a work package on funding and financing. Later, when the infrastructure was set up as an ERIC, he was the vice chair of the Assembly of Members and member of the coordination body. He is also a member of BIOSHARE and BBMRI- LPS within the 7th EU framework program. He contributed to the OECD best practice guidelines for biological resource centres and the OECD guidelines on human biobanks and genetic databases. He participated in the elaboration of the French norm for biobanks NF S96-900 norm and the convenor of an ISO committee drafting an international standard for biobanking. He is a delegate of several French institutions to European and international committees or meetings (OECD, ESF, ERA, ALLEA, EASAC…) and a number of expert committees focusing on the issues related to biobanks within Europe and internationally. He is an expert to the Austrian Federal Ministry of science and research (BMWF) and Genome Quebec. He was also a member of the Inserm ethics committee (ERMES) and the Institutional Review Board (IRB).
  Nilsa Ramirez
Nilsa C. Ramirez, MD, FCAP is the advisor and former chair of the College of American Pathologists Biorepository Accreditation Program (CAP BAP) Committee, regional commissioner of the CAP BAP, and a member of the CAP Surgical Pathology Committee. She is a pathologist, Director of the Biopathology Center and of the Autopsy Division at Nationwide Children’s Hospital, and a professor of clinical pathology at the Ohio State University in Columbus, OH, USA. Her expertise includes biobanking in the context of adult and pediatric cancer clinical trials.
  Martin Golebiewski
  Martin Golebiewski is biochemist by training and works at the Heidelberg Institute for Theoretical Studies (HITS), a private non-profit research institute in Heidelberg (Germany). His main interests are data management and data integration for systems biology and systems medicine, as well as data and model standards in the life sciences. He chairs the 'data processing and integration' working group of the ISO technical committee for biotechnology (ISO/TC 276) and is part of the board of coordinators of the COMBINE network (Computational Modeling in Biology Network). Moreover, Martin Golebiewski coordinated the German NormSys project that laid the foundation for building a bridge between community standards and standardisation bodies, and he is co-leader of the community building working group (WG1) of the European COST action CHARME (Harmonising standardisation strategies to increase efficiency and competitiveness of European life-science research), a research network comprising 30 European countries that aims at harmonizing and merging activities of different standardization communities in the life sciences. Furthermore, he is involved in the reaction kinetics database SABIO-RK and in different systems biology consortia, like the Virtual Liver Network and its successor the Liver Systems Medicine network (LiSyM), as well as in the Infrastructure for Systems Biology Europe (ISBE) and the data management initiative FAIRDOM.
  Brent Schacter
  Coming soon.

Innovative Technology and Its Contribution to Biobanking

  Kurt Zatloukal
  Coming soon.
  Jane Kaye
  Coming soon.
  Hein W. Verspaget
  Hein Verspaget is a biobank coordinator at LUMC and Parelsnoer Institute
  Peter Würtz
  Peter Würtz is Scientific Director and co-founder of Nightingale Health Ltd, a company providing blood biomarker testing by NMR metabolomics. Dr. Würtz is also an Academy of Finland Research Fellow at the University of Helsinki. Dr. Würtz’s research focuses on applications of metabolic biomarker profiling in large population studies and biobanks on cardiovascular diseases and diabetes, with the aims of enhanced understanding of disease mechanisms and early prevention targeted to the right patients.
  Bart Scheerder
  Coming soon.
  Jaana Sinipuro
  Jaana works as a project director at Sitra, the Finnish Innovation Fund. Sitra is a future fund that collaborates with partners from different sectors to research, trial and implement bold new ideas that shape the future. “Isaacus – Digital Health Hub” aims to combine well-being databases and their users in a seamless and safe manner, and offer single-point access to unique Finnish Data Reserves. The project is done in extensive collaboration with pilot organisations (including biobanks and university hospitals) and top authorities like the Ministry of Social Affairs and Health, the National Institute for Health and Welfare (THL), the Social Insurance Institution of Finland (Kela) and Statistics Finland. Jaana is a certified enterprise architect with 20 years of working experience from advanced analytics and business intelligence both from private and public sector. Before joining Sitra, Jaana worked at SAS Institute as a senior advisor.
  Andrew Brooks
  Andrew Brooks is Principal Investigator and Chief Scientist of RUCDR Infinite Biologics, Chief Scientific Officer of Brooks Life Science Systems, and Chief Operating Officer of the Bioprocessing Solutions Alliance
  Dawn Bowles
  Dr. Bowles is an assistant professor in the division of surgical sciences, Department of Surgery, Duke University Medical Center, Durham, NC, USA. Dr. Bowles is also the co-director of the Duke Human Heart Repository and uses this resource in research projects focused on advanced heart failure biology, treatments, and therapy.
  Christopher Ianelli
  Chris conceptualized and founded iSpecimen to address the growing need for human biospecimens by the life science research community. Chris has successfully managed iSpecimen technology development, including the launch of the iSpecimen Marketplace. Prior to founding iSpecimen, Chris served as managing director at Leerink Swann, a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm. Chris was also a co-founder of Health Insight Technologies (now Humedica), a novel healthcare informatics company. Prior to this, Chris was a co-founder and managing director of Boston Medical & Scientific Advisors (BMSA), a healthcare investment research firm acquired by Leerink Swann. He received both his PhD in immunology and his MD from Tufts University and completed residency, including one year as Chief Resident, in pathology at Brigham & Women’s Hospital/Harvard Medical School.
  Paul Lomax
  Paul Lomax is product manager for TTP Labtech, sample management products. With over 15 years experience in the automation of life science applications he is responsible for TTP Labtech’s range of novel automated -20oC and -80oC storage systems.
  Rainer Nitsche
  Coming soon.